Bruker Co. (NASDAQ:BRKR) Shares Purchased by Sei Investments Co.

Sei Investments Co. increased its position in Bruker Co. (NASDAQ:BRKR - Free Report) by 21.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,006 shares of the medical research company's stock after buying an additional 11,087 shares during the period. Sei Investments Co.'s holdings in Bruker were worth $3,635,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of BRKR. Vaughan Nelson Investment Management L.P. lifted its stake in shares of Bruker by 140.3% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company's stock worth $66,930,000 after purchasing an additional 666,617 shares during the period. State Street Corp grew its position in shares of Bruker by 9.6% in the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company's stock valued at $250,501,000 after purchasing an additional 318,808 shares during the period. Natixis Advisors LLC increased its stake in Bruker by 145.8% in the fourth quarter. Natixis Advisors LLC now owns 360,631 shares of the medical research company's stock valued at $21,140,000 after purchasing an additional 213,937 shares during the last quarter. Geode Capital Management LLC lifted its position in Bruker by 10.8% during the third quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company's stock worth $137,702,000 after buying an additional 193,580 shares during the period. Finally, Edgestream Partners L.P. lifted its position in Bruker by 602.8% during the fourth quarter. Edgestream Partners L.P. now owns 111,805 shares of the medical research company's stock worth $6,554,000 after buying an additional 95,897 shares during the period. Hedge funds and other institutional investors own 79.52% of the company's stock.

Remove Ads

Bruker Stock Down 6.0 %

NASDAQ:BRKR traded down $2.34 during mid-day trading on Tuesday, hitting $36.36. The company had a trading volume of 3,574,949 shares, compared to its average volume of 1,426,716. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. Bruker Co. has a 1 year low of $34.10 and a 1 year high of $90.72. The firm has a market capitalization of $5.52 billion, a price-to-earnings ratio of 47.84, a PEG ratio of 2.16 and a beta of 1.18. The business has a fifty day simple moving average of $47.54 and a 200-day simple moving average of $55.43.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Equities analysts forecast that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a yield of 0.55%. Bruker's dividend payout ratio is currently 26.32%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Barclays dropped their price objective on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Guggenheim reaffirmed a "buy" rating on shares of Bruker in a research report on Monday, February 24th. Stifel Nicolaus decreased their price target on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a report on Friday, February 14th. Bank of America boosted their price objective on shares of Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, December 13th. Finally, UBS Group initiated coverage on Bruker in a research report on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 target price on the stock. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $68.00.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.